文献速递儿科与产科急症消化、代谢与肾脏急症

巴瑞替尼治疗幼年特发性关节炎:一项国际、3期、随机、双盲、安慰剂对照、撤药、疗效与安全性试验

Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
PubMed 文献 · Lancet · 2023-07-06
一句话结论在标准治疗应答不足或不耐受的幼年特发性关节炎患者中,巴瑞替尼较安慰剂显著延长至疾病复发时间(HR 0·241,p<0·0001)。

这项3期、随机、双盲、安慰剂对照、撤药试验在20个国家75个中心纳入220例2至<18岁、对一种或多种传统合成或生物类改善病情抗风湿药(DMARDs)应答不足或不耐受的幼年特发性关节炎患者。开放标签导入期每日一次巴瑞替尼4 mg成人等效剂量,第12周达到JIA-ACR30应答的163例按1:1随机分配至安慰剂(n=81)或继续巴瑞替尼(n=82)。双盲撤药期至疾病复发时间安慰剂组显著短于巴瑞替尼组(HR 0·241 [95% CI 0·128-0·453],p<0·0001),安慰剂组中位至复发时间27·14周(95% CI 15·29-不可估计),巴瑞替尼组不可评估。作者认为,巴瑞替尼对标准治疗应答不足或不耐受的多关节型幼年特发性关节炎等亚型有效且安全性可接受。

要点

  • 随机撤药期安慰剂组至疾病复发时间显著短于巴瑞替尼组:HR 0·241(95% CI 0·128-0·453),p<0·0001。
  • 安慰剂组中位至复发时间27·14周(95% CI 15·29-不可估计),巴瑞替尼组不可评估(<50%发生复发事件)。
  • 163/219例(74%)在开放标签导入期第12周达到至少JIA-ACR30应答并进入随机分配。
  • 双盲撤药期严重不良事件:巴瑞替尼组4/82例(5%,IR 9·7/100患者年 [95% CI 2·7-24·9])vs 安慰剂组3/81例(4%,IR 10·2 [2·1-29·7])。
  • 双盲撤药期治疗中出现感染:巴瑞替尼组31/82例(38%,IR 102·1 [69·3-144·9])vs 安慰剂组15/81例(19%,IR 59·0 [33·0-97·3])/100患者年;巴瑞替尼组1例(1%,IR 2·4 [0·1-13·3])报告肺栓塞严重不良事件,判定与研究治疗相关。

适用人群与场景

  • 年龄2至<18岁,患多关节型幼年特发性关节炎(类风湿因子阳性或阴性)、扩展型少关节型幼年特发性关节炎、附着点炎相关关节炎或幼年银屑病关节炎。
  • 对一种或多种传统合成或生物类改善病情抗风湿药(DMARDs)治疗≥12周后应答不足或不耐受。
  • 研究在20个国家75个中心开展,含2周安全性与药代动力学期、12周开放标签导入期(安全性与药代动力学亚队列为10周)及最长32周安慰剂对照双盲撤药期。

诊断标准与关键阈值

  • 开放标签导入期第12周末达到幼年特发性关节炎-美国风湿病学会(JIA-ACR)30标准(JIA-ACR30应答)者方可进入随机分配。
  • 双盲撤药期主要终点为至疾病复发时间,在全部随机分配患者的意向治疗人群中评估。

处置流程与药物剂量

  • 安全性与药代动力学期确定按年龄给药方案后,开放标签导入期给予巴瑞替尼每日一次4 mg成人等效剂量(片剂或混悬液)。
  • 第12周达到JIA-ACR30应答者按1:1随机分配至安慰剂或继续巴瑞替尼,留在双盲撤药期直至疾病复发或至双盲撤药期结束(第44周)。
  • 患者及与患者或中心直接接触的人员对分组设盲。

红旗征与不能漏的情况

  • 双盲撤药期巴瑞替尼组1例(1%,IR 2·4 [95% CI 0·1-13·3]每100患者年)报告肺栓塞严重不良事件,判定与研究治疗相关。

研究设计与关键结果

  • 3期、随机、双盲、安慰剂对照、撤药、疗效与安全性试验,75个中心、20个国家,2018年12月17日至2021年3月3日纳入220例并至少接受一剂巴瑞替尼(女152例[69%],男68例[31%];中位年龄14·0岁[IQR 12·0-16·0])。
  • 219例在开放标签导入期接受巴瑞替尼,其中163例(74%)第12周至少达到JIA-ACR30应答,随机分配至安慰剂(n=81)或巴瑞替尼(n=82)。
  • 主要终点:安慰剂组至疾病复发时间显著短于巴瑞替尼组(HR 0·241 [95% CI 0·128-0·453],p<0·0001);安慰剂组中位至复发时间27·14周(95% CI 15·29-不可估计),巴瑞替尼组不可评估(<50%发生复发事件)。
  • 安全性与药代动力学期或开放标签导入期:220例中6例(3%)发生严重不良事件;55例(25%)报告治疗中出现感染。
  • 双盲撤药期严重不良事件:巴瑞替尼组4/82例(5%,IR 9·7 [95% CI 2·7-24·9]每100患者年)vs 安慰剂组3/81例(4%,IR 10·2 [2·1-29·7]每100患者年)。
  • 双盲撤药期治疗中出现感染:巴瑞替尼组31/82例(38%,IR 102·1 [95% CI 69·3-144·9]每100患者年)vs 安慰剂组15/81例(19%,IR 59·0 [33·0-97·3]每100患者年)。
  • 双盲撤药期巴瑞替尼组1例(1%,IR 2·4 [95% CI 0·1-13·3]每100患者年)报告肺栓塞严重不良事件,判定与研究治疗相关。

证据类型、等级与局限

  • 证据类型:3期、随机、双盲、安慰剂对照、撤药、疗效与安全性试验;试验注册号ClinicalTrials.gov NCT03773978,已完成。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对标准治疗应答不足或不耐受的多关节型幼年特发性关节炎、扩展型少关节型幼年特发性关节炎、附着点炎相关关节炎和幼年银屑病关节炎,巴瑞替尼有效且安全性可接受。
  • 双盲撤药期巴瑞替尼组治疗中出现感染暴露调整发生率(IR 102·1 [95% CI 69·3-144·9]每100患者年)高于安慰剂组(IR 59·0 [33·0-97·3]每100患者年),巴瑞替尼组报告1例与研究治疗相关的肺栓塞严重不良事件。

指南或共识出处

  • Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial(Lancet);试验注册号ClinicalTrials.gov NCT03773978;资助:Eli Lilly and Company under licence from Incyte。

提炼说明

  • 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Juvenile idiopathic arthritis can be refractory to some or all treatment regimens, therefore new medications are needed to treat this population. This trial assessed the efficacy and safety of baricitinib, an oral Janus kinase 1/2-selective inhibitor, versus placebo in patients with juvenile idiopathic arthritis.

METHODS: This phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial was conducted in 75 centres in 20 countries. We enrolled patients (aged 2 to <18 years) with polyarticular juvenile idiopathic arthritis (positive or negative for rheumatoid factor), extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or juvenile psoriatic arthritis, and an inadequate response (after ≥12 weeks of treatment) or intolerance to one or more conventional synthetic or biologic disease-modifying antirheumatic drugs (DMARDs). The trial consisted of a 2-week safety and pharmacokinetic period, a 12-week open-label lead-in period (10 weeks for the safety and pharmacokinetic subcohort), and an up to 32-week placebo-controlled double-blind withdrawal period. After age-based dosing was established in the safety and pharmacokinetic period, patients received a once-daily 4 mg adult-equivalent dose of baricitinib (tablets or suspension) in the open-label lead-in period. Patients meeting Juvenile Idiopathic Arthritis-American College of Rheumatology (JIA-ACR) 30 criteria (JIA-ACR30 responders) at the end of the open-label lead-in (week 12) were eligible for random assignment (1:1) to receive placebo or continue receiving baricitinib, and remained in the double-blind withdrawal period until disease flare or up to the end of the double-blind withdrawal period (week 44). Patients and any personnel interacting directly with patients or sites were masked to group assignment. The primary endpoint was time to disease flare during the double-blind withdrawal period and was assessed in the intention-to-treat population of all randomly assigned patients. Safety was assessed in all patients who received at least one dose of baricitinib throughout the three trial periods. For adverse events in the double-blind withdrawal period, exposure-adjusted incidence rates were calculated. The trial was registered on ClinicalTrials.gov, NCT03773978, and is completed.

FINDINGS: Between Dec 17, 2018 and March 3, 2021, 220 patients were enrolled and received at least one dose of baricitinib (152 [69%] girls and 68 [31%] boys; median age 14·0 years [IQR 12·0-16·0]). 219 patients received baricitinib in the open-label lead-in period, of whom 163 (74%) had at least a JIA-ACR30 response at week 12 and were randomly assigned to placebo (n=81) or baricitinib (n=82) in the double-blind withdrawal period. Time to disease flare was significantly shorter with placebo versus baricitinib (hazard ratio 0·241 [95% CI 0·128-0·453], p<0·0001). Median time to flare was 27·14 weeks (95% CI 15·29-not estimable) in the placebo group, and not evaluable for patients in the baricitinib group (<50% had a flare event). Six (3%) of 220 patients had serious adverse events during the safety and pharmacokinetic period or open-label lead-in period. In the double-blind withdrawal period, serious adverse events were reported in four (5%) of 82 patients (incidence rate [IR] 9·7 [95% CI 2·7-24·9] per 100 patient-years at risk) in the baricitinib group and three (4%) of 81 (IR 10·2 [2·1-29·7]) in the placebo group. Treatment-emergent infections were reported during the safety and pharmacokinetic or open-label lead-in period in 55 (25%) of 220 patients, and during the double-blind withdrawal period in 31 (38%) of 82 (IR 102·1 [95% CI 69·3-144·9]) in the baricitinib group and 15 (19%) of 81 (IR 59·0 [33·0-97·3]) in the placebo group. Pulmonary embolism was reported as a serious adverse event in one patient (1%; IR 2·4 [95% CI 0·1-13·3]) in the baricitinib group in the double-blind withdrawal period, which was judged to be related to study treatment.

INTERPRETATION: Baricitinib was efficacious with an acceptable safety profile in the treatment of polyarticular juvenile idiopathic arthritis, extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, and juvenile psoriatic arthritis, after inadequate response or intolerance to standard therapy.

FUNDING: Eli Lilly and Company under licence from Incyte.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Ramanan AV, Quartier P, Okamoto N, et al. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial. Lancet. 2023. PMID: 37423231. doi:10.1016/S0140-6736(23)00921-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。